Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.